Table 2.
Comparison between newly diagnosed early breast cancer patients and control subjects with respect to the plasma concentrations of the soluble co-stimulatory, co-inhibitory and dual-activity immune checkpoints.
| ICM | Breast Cancer newly diagnosed (n=72) | Controls (n=45) | p value | |
|---|---|---|---|---|
| Median pg/mL (95%CI) | Median pg/mL (95%CI) | |||
| Co-stimulatory | CD27 | 3342.45 | 4577.35 | 0.0243 |
| (2808.61 – 4107.68) | (3391.13 – 5784.85) | |||
| CD28 | 32914.45 | 46135.18 | 0.1248 | |
| (29326.90 – 42636.04) | (27210.29 – 67544.10) | |||
| CD40 | 1523.32 | 1977.68 | 0.0210 | |
| (1298.16 – 1777.45) | (1404.82 – 2569.56) | |||
| ICOS | 15123.78 | 26506.65 | 0.0087 | |
| (12471.47 – 19942.11) | (15897.52 – 31725.99) | |||
| GITR | 1497.40 | 3797.68 | 0.0001 | |
| (1053.33 – 1969.52) | (1993.96 – 5396.86) | |||
| GITRL | 5886.13 | 7151.12 | 0.0199 | |
| (4959.23 – 6681.22) | (5528.36 – 9878.41) | |||
| CD86 | 11585.17 | 14297.09 | 0.1734 | |
| (9938.61 – 14646.29) | (9391.46 – 20525.14) | |||
| CD80 | 1678.33 | 2329.77 | 0.0735 | |
| (1422.82 – 2039.65) | (1395.01 – 3042.87) | |||
| Co-inhibitory | PD-1 | 12305.41 | 14917.48 | 0.5158 |
| (10260.08 – 15798.61) | (7874.92 – 21795.02) | |||
| PD-L1 | 1647.14 | 3342.62 | 0.0001 | |
| (1269.54 – 2228.88) | (2628.64 – 4750.96) | |||
| CTLA-4 | 1566.38 | 2618.23 | 0.0079 | |
| (1314.46 – 1890.81) | (1578.44 – 3110.47) | |||
| TIM-3 | 3897.66 | 5046.87 | 0.0005 | |
| (3169.51 – 4330.5) | (4732.72 – 5958.87) | |||
| LAG-3 | 131275.90 | 150416.00 | 0.5868 | |
| (106666.3 – 156881.5) | (94508.53 – 187997.2) | |||
| BTLA | 13021.75 | 18147.26 | 0,2349 | |
| (10277.82 – 18548.68) | (11461.86 – 25180.69) | |||
| Dual | TLR-2 | 26831.35 | 30477.20 | 0,1806 |
| (21172.10 – 32396.97) | (20928.44 – 50302.64) | |||
| HVEM | 1865.22 | 2290.19 | 0,0004 | |
| (1671.15 – 2038.38) | (2079.46 – 2618.44) |